Immune checkpoint inhibitors have been game changers in tumor treatment during recent years. With improved therapeutic outcomes observed in a variety of solid tumors, this class of drugs has garnered considerable attention. Lacking of mature T, B, and NK cells, Biocytogen B-NDG mice are worldwide recognized as highly immunodeficient tool mice that are ideal for human cell or tissue transplantation. However, the defective immune system of the model itself makes it impossible to evaluate the efficacy of immunotherapy. Immunodeficient mice reconstituted with human immune cells offer a viable solution to this problem: human immune cells and hematopoietic stem cells are transplanted into B-NDG mice or B-NDG-derived mice to reconstitute their immune system, which can better simulate the human immune system for immunological studies and immune drug evaluation.
Biocytogen currently provides three immune reconstitution models: human peripheral blood mononuclear cell (PBMC) reconstitution, human hematopoietic stem cell (CD34+ HSC) reconstitution, and NK cell reconstitution. The immune reconstitution mouse model aids in the efficacy evaluation of immunotherapy drugs, bolstering the efforts in novel drug development and preclinical evaluation.
Anti-CDX tumor efficacy study of antibodies in B-NDG mice reconstituted with human NK cells
Efficacy study of IMAB362 antibody in B-NDG hIL15 mice reconstituted with human NK cells
The humanized B-NDG hIL15 mice model reconstituted with NK cells (2E6) was subcutaneously transplanted with A549-hCLDN18.2 cells (1E6). The mice were grouped 11 days after tumor cell implantation and treated with IMAB362, which showed significant tumor-suppressive effects. The results indicate that the mice provide a powerful preclinical model for in vivo antibody evaluation. Values are expressed as mean ± SEM.